Navigation Links
Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
Date:5/19/2008

with millions of people affected by this debilitating condition," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "With the designation of RDEA594 as our clinical candidate for the treatment of gout, we now expect to have five novel candidates in clinical testing during the second half of 2008, positioning us with the potential to have a broad-based, late-stage pipeline in 2009. This finding also allows us to focus our future development efforts with RDEA806 on the treatment of HIV."

The Company plans to initiate a Phase 1 clinical study of RDEA594 in the second half of this year. As previously announced, the Company also plans to conduct a Phase 2 proof-of-concept clinical study in patients with gout, to confirm RDEA594's activity in the target population using its prodrug, RDEA806. This study is on track to be initiated in the second quarter of this year.

The EULAR presentation details are as follows:

Date/Time: Thursday, June 12, 2008 from 11:45 a.m. - 1:30 p.m. CEST

Title: Safety and Uric Acid Lowering Effect in Humans Following Multiple

Doses of RDEA806, A Novel Prodrug for the Potential Treatment of

Hyperuricemia

Location: Le Palais de Congres de Paris - Level 1 (Abstract # THU0356)

Date/Time: Thursday, June 12, 2008 from 11:45 a.m. - 1:30 p.m. CEST

Title: Mode of Action of RDEA594 as a Uric Acid Lowering Agent in Humans

Following Multiple Doses of its Prodrug, RDEA806

Location: Le Palais de Congres de Paris - Level 1 (Abstract # THU0357)

About Gout

An estimated 3-5 million people in the United States suffer from gout, which is the most common form of inflammatory arthritis in men over 40. Gout, also known as metabolic arthritis, is a painful and debilitating disease caused by abnormally elevated levels of uric acid in the blood stream. These abnormally elevated levels lead to the deposition of uric acid crystals in and around the connecti
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
2. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
3. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
4. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
5. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
10. Neurocrine Biosciences Reports First Quarter 2008 Results
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Magnaquest, a leading Subscription ... cloud computing operators has signed a Proof of ... Internet of Things (IoT) related initiative. The PoC ... model.      (Logo: http://photos.prnewswire.com/prnh/20140807/700645 ) ... business innovations to make healthcare services more accessible ...
(Date:7/30/2015)...  ResMed Inc. (NYSE: RMD ) today announced ... for the quarter was $453.1 million, a 9 percent ... (a 17 percent increase on a constant currency basis). ... ended June 30, 2014.  Diluted earnings per share for ... June 30, 2014.  The results for ...
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... MedImmune today announced,that it has initiated a Phase 1/2a ... children one month to 12 months of age to,help ... most common respiratory infection in infants and can cause ... a serious respiratory disease that can have significant effects,on ...
... Partner to Make Direct Investment in CEL-SCI, ... CVM ) announced today that it has expanded ... Co., Ltd. ("Orient,Europharma"), a leading pharmaceutical company from ... also cover South Korea,the Philippines, Australia and New ...
Cached Medicine Technology:MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 3
(Date:7/31/2015)... ... 31, 2015 , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company ... , BioViva announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to ... a cure. MaxLife will grant 100% of the money raised to BioViva to help ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has increased a patient's ... heart rate of 150 beats versus 100 beats, this is a big deal," says ... give life back to patients with heart disease," he adds. People with angina are ...
(Date:7/31/2015)... York, NY (PRWEB) , ... July 31, 2015 , ... ... kidney disease, according to a study published today in Nature Communications and led by ... conducted in mice, suggests that variations in the gene RTN1 led to greater production ...
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased ... in Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based ... script display logic shows the script components to the agent only when wanted, and ...
(Date:7/31/2015)... ... , ... According to WFLA on July 16th, Sarasota has seen ... overdoses. Thricefold deaths have held steady over the last “couple of months” according to ... which was spurred by the crackdown of prescription painkillers. Many users who were addicted ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3
... reason to deny insurers access to genetic information, argues a ... BMJ. ,Only if we refuse to give ... them seeking genetic test results, says Professor Soren Holm from ... to any health information they would only be able to ...
... of herbal products and medicines has the potential to reach ... the creation of exclusive export promotion zones (EPZ) across ... can be accelerated with the setting up of EPZs in ... rate of over 25 percent in countries like the US, ...
... less than three dollars a year per patient could ... from the trauma and torment of epilepsy, a new ... 85 percent of epilepsy sufferers in the developing world ... the drugs most often prescribed to impede the terrible ...
... find the perfect present this Father's Day? What better way to ... keep him healthy and vital for years to come . This ... check themselves out -- and then get checked out by their ... and over have diabetes. The symptoms of type 2 diabetes, the ...
... getting rid of smoking was more difficult for him than ... ,The former hellraiser, who quit his nicotine addiction in ... hooked to smoking again.,He revealed that before he had kicked ... ,"They're all a b**ger to kick, but I'd ...
... with Prof Vijay K Varadan, an Indian born US ... production of ``glucose watches''. The talks are in the ... ,Varadan holds the post of Director of the Centers ... Density Electronics Center (HiDEC) and Neurosurgery Research Programme in University ...
Cached Medicine News:Health News:Should Genetic Information Be Disclosed to Insurers? 2Health News:Export of Herbal Products to Reach Rs.120 Billion by 2012: Study 2Health News:Small Change Could Stop Epilepsy Seizures for Millions 2Health News:Drag Dad to the Doctor This Father's Day 2Health News:Titan may Produce Glucose Watches Soon 2
Are you looking for an inexpensive, effective Blood and Infusion Warmer? , ,Animec is an economical fluid warmer that uses standard I.V. tubing instead of special disposable sets....
... The reliable, rugged and easy-to-use solution that's ... is required., ,Symeon's light weight and ... moved into any working position. It can ... And excessive cable "spaghetti syndrome" is minimized ...
... Narkomed 6400 Series anesthesia workstation provides ... technologies are combined to provide true ... user. State of the art computer ... onto a single color touchscreen display ...
... Developed to be used in facilities where ... the latest ventilation and gas delivery technologies ... the ability and the functionality of the ... to create yourself a workplace environment that ...
Medicine Products: